Your session is about to expire
← Back to Search
Atezolizumab + Bevacizumab vs Radiation Therapy for Liver Cancer (ADVANCE HCC Trial)
ADVANCE HCC Trial Summary
This trial is testing two different treatments for people with a certain type of liver cancer. The first group of people will get a drug called Atezolizumab, and the second group will get a different drug called Bevacizumab. The trial will compare how well each treatment works.
ADVANCE HCC Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowADVANCE HCC Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.ADVANCE HCC Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am older than 18 years.I have not had major surgery or a significant injury in the last 28 days.I have coughed up blood in the last 4 weeks.My liver cancer has spread to the main branches of the portal vein.I haven't had a stroke or blood clot in the arteries in the last year.I have not had bleeding from esophageal or gastric varices, and my recent endoscopy was normal.Your tumor is smaller than 10 centimeters when measured by CT or MRI.Your blood test shows that you have low hemoglobin levels.I need help with my daily activities due to my health condition.I have HIV, HBV, or HCV but my HBV is under control and I'm treated for it.I have not had a severe infection or been hospitalized for one in the last 4 weeks.I haven't taken strong CYP3A4 inducers in the last 14 days.I haven't taken any immune-boosting drugs in the last 4 weeks or longer.I have had treatments for liver cancer but none within the last 28 days.My liver functions well despite my illness.I have a wound or bone fracture that hasn't fully healed.I have serious heart or blood pressure problems.I haven't had cancer, except for certain types, in the last 5 years.Your blood clotting time is longer than normal.Your blood creatinine levels are higher than 1.5 times the usual upper limit.My liver cancer is confirmed by biopsy and hasn't spread.I am currently using or have recently used blood thinners or certain heart medications.I haven't taken strong immune system medications in the last 14 days.I do not have a history of severe autoimmune diseases or known allergies to Bevacizumab or ICI components.I have active tuberculosis.You have had a serious allergic reaction to contrast dye in the past.I have had issues like a GI perforation, abdominal fistula, or abscess before.I have a history of certain lung conditions or currently have lung inflammation.I have had a previous transplant of stem cells or an organ.I have not received a live vaccine recently.I have moderate to severe nerve issues and a history of low magnesium levels.Your blood platelet count is less than 75 billion per liter without needing a blood transfusion.Your urine has a high level of protein, unless a 24-hour urine test shows a lower amount.
- Group 1: Neoadjuvant Atezolizumab/Bevacizumab
- Group 2: Neoadjuvant SBRT
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the geographic distribution of this research endeavor?
"This medical trial is currently taking place across 12 sites, including the Ottawa Regional Cancer Centre in Ottawa, McGill Cedars Cancer Centre in Montréal and Tom Baker Cancer Centre in Calgary."
To what extent can Neoadjuvant treatment be detrimental to patient health?
"Our team at Power assessed Neoadjuvant's safety to be a 2, as this is still in the second phase of clinical trials and there has not been sufficient evidence gathered on its efficacy."
Is there a recruitment process ongoing for this investigation?
"Affirmative. According to clinicaltrials.gov, this trial is actively seeking 70 participants from 9 diverse locations. The study was initially made available on October 18th of 2022 and the entry has been modified since that date."
What is the upper limit of participants involved in this investigation?
"This clinical trial necessitates the enrollment of 70 suitable patients from multiple sites, including Ottawa Regional Cancer Centre and McGill Cedars Cancer Centre."
Share this study with friends
Copy Link
Messenger